5 Most Promising Gene Therapy Companies to Watch

4. Prime Medicine, Inc. (NASDAQ:PRME)

Market Capitalization as of November 12, 2022: $2.02 billion

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company that uses gene editing. The firm’s technologies enable treatments to precisely target genomes by blending proteins. It is headquartered in Cambridge, Massachusetts.

Prime Medicine, Inc. (NASDAQ:PRME) is currently valued at $2.02 billion by the stock market. Its technology was formulated at the Harvard University and the Massachusetts Institute of Technology, and the main programs that are currently under development can bring the firm as much as $13 billion in revenue. The firm also just completed its initial public offering (IPO) of 10 million shares in late October, as it sold the shares at $17 each. The current share price has appreciated since then and stands at $21 per share.